ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D TUESDAY, June 27, 2023 (HealthDay News) -- Once-weekly tirzepatide provides substantial and clinically meaningful reductions in body weight in adults with obesity and type 2 diabetes, according to a study published online June 26 in the The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 23 to 26 in San Diego
Rate of first-time prescriptions The table below shows the percentage of the population who received a first-time diagnosis of T2D, CVD, or sleep apnea within 15 days of their first-time GLP-1 prescriptions
Harmful cholesterol, triglycerides and free fatty acid levels declined while beneficial HDL cholesterol rose
157 While corticosteroids and other immunosuppressive agents exert broad anti-inflammatory effects, direct inhibition of NLRP3 inflammasome activation represents a more specific therapeutic strategy, potentially allowing for more effective suppression of inflammation with reduced off-target effects
